Symbols / XTNT $0.48 -0.70% Xtant Medical Holdings, Inc.

Healthcare • Medical Devices • United States • ASE
XTNT Chart
About

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Medical Devices Market Cap 67.46M
Enterprise Value 79.12M Income 4.97M Sales 133.93M
Book/sh 0.36 Cash/sh 0.12 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E 16.05 Forward P/E -24.08 PEG 1.74
P/S 0.50 P/B 1.32 P/C —
EV/EBITDA 6.33 EV/Sales 0.59 Quick Ratio 1.18
Current Ratio 2.65 Debt/Eq 56.36 LT Debt/Eq —
EPS (ttm) 0.03 EPS next Y -0.02 EPS Growth —
Revenue Growth 2.70% Earnings 2026-05-12 ROA 4.84%
ROE 10.59% ROIC — Gross Margin 62.92%
Oper. Margin -2.92% Profit Margin 3.71% Shs Outstand 140.07M
Shs Float 54.10M Short Float 0.06% Short Ratio 0.28
Short Interest — 52W High 0.95 52W Low 0.39
Beta -0.16 Avg Volume 163.17K Volume 119.34K
Target Price $1.10 Recom Strong_buy Prev Close $0.48
Price $0.48 Change -0.70%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.10
Mean price target
2. Current target
$0.48
Latest analyst target
3. DCF / Fair value
$0.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.48
Low
$1.00
High
$1.20
Mean
$1.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 main BTIG Buy → Buy $1
2025-11-11 main BTIG Buy → Buy $2
2024-05-16 main BTIG Buy → Buy $3
2023-12-05 init BTIG — → Buy $2
2023-07-11 main Craig-Hallum Buy → Buy $1
2023-04-26 init Craig-Hallum — → Buy $1
2019-05-17 down Maxim Group Buy → Hold —
2016-12-08 init Maxim Group — → Buy $2
2016-11-30 init Aegis Capital — → Buy $4
News
RSS: Latest XTNT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-14 BAKEWELL JOHN K Director — 158,228 $0.00 $0
2025-11-14 BAKEWELL JOHN K Director — 158,228 $0.00 $0
2025-11-14 LIPSCHULTZ TYLER P Director — 158,228 $0.00 $0
2025-11-14 VIZIRGIANAKIS STAVROS G Director — 553,797 $0.00 $0
2025-11-14 BROWNE SEAN E. Chief Executive Officer — 394,937 $0.00 $0
2025-11-14 NEILS SCOTT C Chief Financial Officer — 263,291 $0.00 $0
2025-11-14 SCHALLENBERGER MARK A. Chief Operating Officer — 292,253 $0.00 $0
2025-11-14 BEESON JONN R. Director — 158,228 $0.00 $0
2025-11-14 JAIN ABHINAV Director — 158,228 $0.00 $0
2025-04-10 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 73,114,592 $0.42 $30,708,129
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
133.93
+14.21%
117.27
+28.44%
91.30
+57.50%
57.97
Operating Revenue
133.93
+14.21%
117.27
+28.44%
91.30
+57.50%
57.97
Cost Of Revenue
49.65
+1.23%
49.05
+36.88%
35.84
+38.73%
25.83
Reconciled Cost Of Revenue
49.65
+1.23%
49.05
+36.88%
35.84
+38.73%
25.83
Gross Profit
84.27
+23.54%
68.22
+22.98%
55.47
+72.60%
32.14
Operating Expense
76.99
-4.11%
80.29
+22.35%
65.62
+68.74%
38.89
Research And Development
2.10
-11.87%
2.38
+78.52%
1.34
+46.01%
0.92
Selling General And Administration
74.89
-3.87%
77.91
+21.18%
64.29
+69.28%
37.98
Selling And Marketing Expense
45.51
-7.52%
49.21
+28.03%
38.44
+70.73%
22.52
General And Administrative Expense
29.38
+2.38%
28.69
+10.99%
25.85
+67.18%
15.46
Other Gand A
29.38
+2.38%
28.69
+10.99%
25.85
+67.18%
15.46
Total Expenses
126.64
-2.09%
129.34
+27.48%
101.46
+56.76%
64.72
Operating Income
7.28
+160.33%
-12.07
-18.86%
-10.16
-50.38%
-6.75
Total Operating Income As Reported
7.28
+160.33%
-12.07
-18.86%
-10.16
-50.38%
-6.75
EBITDA
15.89
+301.76%
-7.88
-255.23%
5.08
+193.43%
-5.43
Normalized EBITDA
12.67
+260.78%
-7.88
-14.51%
-6.88
-26.73%
-5.43
Reconciled Depreciation
5.22
+23.65%
4.22
+33.08%
3.17
+145.67%
1.29
EBIT
10.67
+188.18%
-12.10
-736.61%
1.90
+128.27%
-6.72
Total Unusual Items
3.22
+64320.00%
0.01
-99.96%
11.96
0.00
Total Unusual Items Excluding Goodwill
3.22
+64320.00%
0.01
-99.96%
11.96
0.00
Special Income Charges
3.28
0.00
-100.00%
11.69
0.00
Restructuring And Mergern Acquisition
—
0.00
+100.00%
-11.69
0.00
Net Income
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Pretax Income
7.00
+143.05%
-16.26
-1468.18%
-1.04
+87.68%
-8.42
Net Non Operating Interest Income Expense
-3.58
+14.01%
-4.16
-49.16%
-2.79
-67.91%
-1.66
Interest Expense Non Operating
3.67
-11.75%
4.16
+41.59%
2.94
+73.64%
1.69
Net Interest Income
-3.58
+14.01%
-4.16
-49.16%
-2.79
-67.91%
-1.66
Interest Expense
3.67
-11.75%
4.16
+41.59%
2.94
+73.64%
1.69
Interest Income Non Operating
0.09
0.00
-100.00%
0.15
+380.65%
0.03
Interest Income
0.09
0.00
-100.00%
0.15
+380.65%
0.03
Other Income Expense
3.29
+11864.29%
-0.03
-100.24%
11.91
—
Other Non Operating Income Expenses
0.07
+321.21%
-0.03
+32.65%
-0.05
—
Gain On Sale Of Security
-0.06
-1300.00%
0.01
-98.11%
0.27
—
Gain On Sale Of Business
3.28
0.00
—
—
Tax Provision
2.03
+984.49%
0.19
+111.02%
-1.70
-2559.42%
0.07
Tax Rate For Calcs
0.00
+38.10%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.93
+88860.95%
0.00
-99.96%
2.51
0.00
Net Income Including Noncontrolling Interests
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Net Income From Continuing Operation Net Minority Interest
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Net Income From Continuing And Discontinued Operation
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Net Income Continuous Operations
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Normalized Income
2.69
+116.33%
-16.45
-87.23%
-8.79
-3.57%
-8.48
Net Income Common Stockholders
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Diluted EPS
0.03
+125.00%
-0.12
-1300.00%
0.01
+111.11%
-0.09
Basic EPS
0.04
+133.33%
-0.12
-1300.00%
0.01
+111.11%
-0.09
Basic Average Shares
139.53
+4.39%
133.67
+12.24%
119.09
+26.58%
94.09
Diluted Average Shares
150.04
+12.25%
133.67
+5.42%
126.79
+34.76%
94.09
Diluted NI Availto Com Stockholders
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
94.14
+0.33%
93.84
+1.32%
92.61
+53.77%
60.23
Current Assets
78.25
+16.58%
67.12
+3.46%
64.87
+31.53%
49.32
Cash Cash Equivalents And Short Term Investments
17.05
+175.09%
6.20
+8.47%
5.71
-71.84%
20.30
Cash And Cash Equivalents
17.05
+175.09%
6.20
+8.47%
5.71
-71.84%
20.30
Receivables
28.27
+36.81%
20.66
-0.34%
20.73
+91.02%
10.85
Accounts Receivable
17.80
-13.83%
20.66
-0.34%
20.73
+91.02%
10.85
Gross Accounts Receivable
19.97
-9.63%
22.10
+2.06%
21.65
+90.46%
11.37
Allowance For Doubtful Accounts Receivable
-2.17
-50.66%
-1.44
-56.20%
-0.92
-78.64%
-0.52
Inventory
30.26
-21.67%
38.63
+4.74%
36.88
+113.39%
17.29
Raw Materials
5.69
-14.09%
6.62
-8.90%
7.27
+29.16%
5.63
Work In Process
4.80
+70.66%
2.81
+80.03%
1.56
+95.74%
0.80
Finished Goods
19.77
-32.28%
29.20
+4.08%
28.05
+158.35%
10.86
Prepaid Assets
—
—
—
—
Restricted Cash
0.28
+1150.00%
0.02
-89.42%
0.21
-0.48%
0.21
Other Current Assets
2.39
+49.22%
1.60
+20.38%
1.33
+97.62%
0.67
Total Non Current Assets
15.90
-40.50%
26.72
-3.68%
27.74
+154.27%
10.91
Net PPE
9.39
-14.29%
10.96
+7.29%
10.21
+42.57%
7.17
Gross PPE
31.60
+2.61%
30.80
+3.02%
29.89
+18.97%
25.13
Accumulated Depreciation
-22.21
-11.95%
-19.84
-0.80%
-19.68
-9.55%
-17.96
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.61
-0.12%
1.61
+3.53%
1.56
+22.55%
1.27
Other Properties
25.50
+2.74%
24.83
+3.49%
23.99
+21.45%
19.75
Leases
4.48
+2.92%
4.36
+0.21%
4.35
+5.90%
4.11
Goodwill And Other Intangible Assets
6.37
-59.30%
15.66
-9.94%
17.39
+389.91%
3.55
Goodwill
6.07
-16.82%
7.30
+0.00%
7.30
+127.83%
3.21
Other Intangible Assets
0.30
-96.42%
8.36
-17.14%
10.09
+2831.69%
0.34
Other Non Current Assets
0.13
+29.13%
0.10
-26.95%
0.14
-28.43%
0.20
Total Liabilities Net Minority Interest
43.19
-15.10%
50.87
+23.29%
41.26
+58.35%
26.06
Current Liabilities
29.48
+3.16%
28.58
+24.32%
22.99
+51.07%
15.22
Payables And Accrued Expenses
14.47
-7.77%
15.69
-10.21%
17.47
+94.45%
8.99
Payables
12.75
-8.16%
13.89
-12.91%
15.94
+100.45%
7.95
Accounts Payable
3.84
-51.45%
7.92
+12.25%
7.05
+102.12%
3.49
Other Payable
6.73
+20.86%
5.57
-37.40%
8.89
+99.15%
4.46
Current Accrued Expenses
1.72
-4.77%
1.80
+17.92%
1.53
+48.16%
1.03
Total Tax Payable
2.18
+441.69%
0.40
—
—
Current Debt And Capital Lease Obligation
15.01
+16.46%
12.89
+133.68%
5.52
-11.47%
6.23
Current Debt
14.36
+18.46%
12.12
+162.22%
4.62
-19.08%
5.71
Other Current Borrowings
3.50
—
—
2.33
Current Capital Lease Obligation
0.66
-14.90%
0.77
-13.74%
0.90
+72.12%
0.52
Total Non Current Liabilities Net Minority Interest
13.71
-38.51%
22.29
+22.00%
18.27
+68.57%
10.84
Long Term Debt And Capital Lease Obligation
13.70
-38.42%
22.25
+23.33%
18.04
+66.44%
10.84
Long Term Debt
11.03
-49.97%
22.04
+28.37%
17.17
+77.22%
9.69
Long Term Capital Lease Obligation
2.68
+1156.81%
0.21
-75.66%
0.88
-24.11%
1.15
Non Current Deferred Liabilities
0.01
-88.10%
0.04
+100.00%
0.02
0.00
Non Current Deferred Taxes Liabilities
0.01
-88.10%
0.04
+100.00%
0.02
0.00
Stockholders Equity
50.95
+18.60%
42.96
-16.33%
51.35
+50.27%
34.17
Common Stock Equity
50.95
+18.60%
42.96
-16.33%
51.35
+50.27%
34.17
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
140.04
+0.71%
139.05
+6.81%
130.18
+19.57%
108.87
Ordinary Shares Number
140.04
+0.71%
139.05
+6.81%
130.18
+19.57%
108.87
Additional Paid In Capital
305.44
+0.89%
302.74
+2.86%
294.33
+5.93%
277.84
Retained Earnings
-254.49
+1.92%
-259.46
-6.77%
-243.01
+0.27%
-243.67
Gains Losses Not Affecting Retained Earnings
0.00
+100.00%
-0.32
-1189.66%
0.03
0.00
Other Equity Adjustments
—
-0.32
-1189.66%
0.03
—
Total Equity Gross Minority Interest
50.95
+18.60%
42.96
-16.33%
51.35
+50.27%
34.17
Total Capitalization
61.98
-4.65%
65.00
-5.13%
68.52
+56.22%
43.86
Working Capital
48.76
+26.54%
38.53
-7.98%
41.88
+22.81%
34.10
Invested Capital
76.34
-1.02%
77.12
+5.45%
73.14
+47.54%
49.57
Total Debt
28.72
-18.29%
35.14
+49.17%
23.56
+38.00%
17.07
Net Debt
8.33
-70.21%
27.96
+73.94%
16.07
—
Capital Lease Obligations
3.33
+238.48%
0.98
-44.35%
1.77
+5.80%
1.67
Net Tangible Assets
44.58
+63.27%
27.30
-19.60%
33.96
+10.91%
30.62
Tangible Book Value
44.58
+63.27%
27.30
-19.60%
33.96
+10.91%
30.62
Line Of Credit
10.86
-10.42%
12.12
+162.22%
4.62
+36.79%
3.38
Non Current Accrued Expenses
—
0.00
-100.00%
0.21
0.00
Notes Receivable
10.46
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
12.55
+205.46%
-11.90
-25.02%
-9.52
-78.15%
-5.34
Cash Flow From Continuing Operating Activities
12.55
+205.46%
-11.90
-25.02%
-9.52
-78.15%
-5.34
Net Income From Continuing Operations
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Depreciation Amortization Depletion
5.22
+23.65%
4.22
+33.08%
3.17
+145.67%
1.29
Depreciation And Amortization
5.22
+23.65%
4.22
+33.08%
3.17
+145.67%
1.29
Other Non Cash Items
0.46
-10.83%
0.52
+104.58%
-11.29
-4864.56%
0.24
Stock Based Compensation
2.89
-29.75%
4.12
+50.31%
2.74
+11.16%
2.46
Provisionand Write Offof Assets
5.07
+287.84%
1.31
+53.16%
0.85
-58.44%
2.06
Deferred Tax
—
0.02
+101.10%
-1.90
0.00
Deferred Income Tax
—
0.02
+101.10%
-1.90
0.00
Operating Gains Losses
-3.03
-1047.73%
-0.26
-129.57%
-0.12
-23.66%
-0.09
Gain Loss On Sale Of PPE
0.25
+195.08%
-0.26
-129.57%
-0.12
-23.66%
-0.09
Change In Working Capital
-3.05
+43.05%
-5.35
-47.19%
-3.63
-29.28%
-2.81
Change In Receivables
-0.59
+21.72%
-0.76
+91.36%
-8.74
-121.67%
-3.94
Changes In Account Receivables
-0.59
+21.72%
-0.76
+91.36%
-8.74
-121.67%
-3.94
Change In Inventory
-2.00
+19.85%
-2.49
-32.24%
-1.89
-63.72%
-1.15
Change In Prepaid Assets
-1.54
-605.05%
-0.22
-199.09%
0.22
-15.71%
0.26
Change In Payables And Accrued Expense
1.08
+157.44%
-1.88
-127.81%
6.77
+234.88%
2.02
Change In Accrued Expense
4.20
+244.01%
-2.92
-176.95%
3.79
+230.54%
1.15
Change In Payable
-3.12
-401.74%
1.03
-65.34%
2.98
+240.57%
0.88
Change In Account Payable
-3.12
-401.74%
1.03
-65.34%
2.98
+240.57%
0.88
Investing Cash Flow
7.90
+311.77%
-3.73
+84.95%
-24.78
-1489.74%
-1.56
Cash Flow From Continuing Investing Activities
7.90
+311.77%
-3.73
+84.95%
-24.78
-1489.74%
-1.56
Net PPE Purchase And Sale
-2.15
+42.36%
-3.73
-191.18%
-1.28
+17.83%
-1.56
Purchase Of PPE
-2.38
+42.09%
-4.11
-182.49%
-1.46
+17.46%
-1.76
Sale Of PPE
0.23
-39.43%
0.38
+118.86%
0.17
-14.63%
0.20
Capital Expenditure
-2.38
+42.09%
-4.11
-182.49%
-1.46
+17.46%
-1.76
Net Business Purchase And Sale
10.05
0.00
+100.00%
-23.50
0.00
Purchase Of Business
—
0.00
+100.00%
-23.50
0.00
Gain Loss On Sale Of Business
-3.28
0.00
—
—
Financing Cash Flow
-9.57
-159.54%
16.07
-18.37%
19.69
+118.30%
9.02
Cash Flow From Continuing Financing Activities
-9.57
-159.54%
16.07
-18.37%
19.69
+118.30%
9.02
Net Issuance Payments Of Debt
-9.33
-175.04%
12.43
+101.18%
6.18
+2223.71%
-0.29
Issuance Of Debt
100.07
-14.94%
117.64
+41.36%
83.22
+53.46%
54.23
Repayment Of Debt
-109.40
-3.98%
-105.21
-36.56%
-77.04
-41.30%
-54.52
Long Term Debt Issuance
0.00
-100.00%
5.00
+0.00%
5.00
0.00
Long Term Debt Payments
-8.07
-12310.77%
-0.07
-3.17%
-0.06
-26.00%
-0.05
Net Long Term Debt Issuance
-8.07
-263.47%
4.93
-0.04%
4.94
+9974.00%
-0.05
Short Term Debt Issuance
100.07
-11.16%
112.64
+44.01%
78.22
+44.24%
54.23
Short Term Debt Payments
-101.33
+3.63%
-105.14
-36.59%
-76.98
-41.32%
-54.47
Net Short Term Debt Issuance
-1.26
-116.84%
7.50
+503.22%
1.24
+615.77%
-0.24
Net Common Stock Issuance
-0.07
-101.46%
4.46
-68.20%
14.01
+50.48%
9.31
Common Stock Payments
-0.07
—
—
—
Repurchase Of Capital Stock
-0.07
—
—
—
Proceeds From Stock Option Exercised
0.00
-100.00%
0.01
0.00
—
Net Other Financing Charges
-0.17
+78.89%
-0.83
-65.80%
-0.50
—
Changes In Cash
10.88
+2332.89%
0.45
+103.06%
-14.61
-789.06%
2.12
Effect Of Exchange Rate Changes
0.23
+255.70%
-0.15
-720.83%
0.02
0.00
Beginning Cash Position
6.22
+5.03%
5.92
-71.12%
20.51
+11.53%
18.39
End Cash Position
17.33
+178.54%
6.22
+5.03%
5.92
-71.12%
20.51
Free Cash Flow
10.16
+163.49%
-16.01
-45.92%
-10.97
-54.41%
-7.11
Interest Paid Supplemental Data
—
3.64
+42.55%
2.55
+75.52%
1.45
Common Stock Issuance
—
4.46
-68.20%
14.01
+50.48%
9.31
Issuance Of Capital Stock
—
4.46
-68.20%
14.01
+50.48%
9.31
Sale Of Business
10.05
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category